NICE turns down BMS's Yervoy for first-line use
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has said that it will not recommend Bristol-Myers Squibb's melanoma drug Yervoy (ipilimumab) for use in the first-line on the NHS because of uncertainties in the data the company submitted.